Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery.

ABSTRACT: Early-stage drug discovery relies on high-throughput screenings, which are costly and time-intensive, limiting access for academic laboratories and small companies. A key bottleneck is the lack of miniaturization and the separation of compound synthesis from screening. We present a nanoliter droplet array platform integrating synthesis, characterization, and cell-based screening of 325 MEK (mitogen-activated protein kinase kinase) inhibitors, targeting the MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) pathway, implicated in colorectal and pancreatic cancer. The platform enables on-chip synthesis, MALDI-MSI (matrix-assisted laser desorption/ionization-mass spectrometry imaging) characterization, and cell-based screening within 200 nL droplets containing 2

SUBMITTER: Seifermann M 

PROVIDER: S-EPMC12643352 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature